Simian immunodeficiency virus (SIV) infection of rhesus macaques is a model for human immunodeficiency virus (HIV) infection in humans. Inactivated and modified live whole-virus vaccines have provided limited
protective immunity against SIV in rhesus macaques. Because of safety concerns in the use of inactivated and live whole-virus vaccines, we evaluated the protective immunity of vaccinia virus recombinants expressing the surface glycoprotein (gpl30) of SlVmac and subunit preparations of gpl30 expressed in mammalian cells (CHO). Three groups of animals were immunized with recombinant SIV gpl30. The first group received SIV gpl30 purified from genetically engineered CHO cells (cSlVgpl3O), the second group was vaccinated with recombinant vaccinia virus expressing SlVmac gpl30 (vSIVgpl30), and the third group was first primed with vSIVgpl30 and then given a booster immunization with cSIVgpl30. Although anti-gpl30 binding antibodies were elicited in all three groups, neutralizing antibodies were transient or undetectable. None of the immunized animals resisted intravenous challenge with a low dose of cell-free virus. However, the group primed with vSIVgpl30 and then boosted with cSIVgpl30 had the lowest antigen load (p27) compared with the other groups. The results of these studies suggest that immunization of humans with HIV type 1 surface glycoprotein may not provide protective immunity against virus infection.
The development of an effective vaccine against the human immunodeficiency virus (HIV) is a major public health priority. Many vaccine strategies have been targeted to the HIV envelope glycoprotein (gpl60). The gpl20 (extracellular) surface domain of the envelope glycoprotein binds to the CD4 receptor as the first step in infection. Thus, gpl20 plays a role in viral tropism for T cells and macrophages (41) . In healthy HIV-infected individuals, neutralizing determinants and T-cell epitopes are located in hypervariable as well as conserved domains of the gpl20 molecule (14, 33) . In some but not all studies, the presence of antibodies to surface gpl20 epitopes correlates with a lack of viral transmission from an infected mother to infants (8) . Furthermore, chimpanzees immunized with recombinant HIV gp120 were protected from intravenous challenge with HIV (1). However, this model is limited to prevention of infection since HIV does not cause clinical disease in chimpanzees.
Simian immunodeficiency virus (SIV) is a T-lymphotropic lentivirus genetically related to HIV, and SIV causes an AIDS-like disease in rhesus macaques (6, 10). Accordingly, SIV in macaques is a model for the study of HIV infection and disease in humans. This model also offers opportunities to test and develop vaccine strategies as well as antiviral drugs (11) .
The SIV envelope precursor, gp160, is cleaved into the surface gpl30 and the transmembrane gp4l. Macaques have been protected against SIV and HIV type 2 (HIV-2) infection by immunization with a whole inactivated virus (2, 7, 19, 24, * Corresponding author. 30, 35, 38) , although the observed protection may have been due to immune responses to cellular as well as viral antigens (20, 37) . Such immunized animals had envelope-specific neutralizing (SN) antibodies that bound to SIVmac recombinant gpl30 expressed in CHO cells (13) . Protection has also been achieved with a modified live SIV vaccine (26) , and partial protection has been achieved with SIV gpl30 prepared from virions (31, 32) . Thus, gpl30 is a logical candidate for the development of a subunit vaccine against SIV. For vaccine studies in the SIV-macaque system, we focused on the external domain of the SIVmaclAll envelope gpl30. The molecular clone SIVmaclAll was obtained from the biological isolate SIVmac251. SIVmaclAll is infectious and induces syncytia (23) . The introduction of an NcoI site to provide an initiation codon (ATG) for gpl30, the insertion of a stop codon (TAG) in the processing site between gpl30 and gp41, and excision of the gpl30-coding sequence from plasmid pGEM SIVmacgpl3O-II by digestion with NcoI and Sall restriction endonucleases have been described previously (34) . To prepare a vaccinia virus (VV) recombinant that expresses SIV gp130 (vSIVgp130), we cloned the DNA fragment of the gp130-coding sequence into the SmaI site of pVY6 transfer vector to generate pVYSIV macgpl30. The pVY6 vector directs the insertion of genes into the hemagglutinin region of the VV genome (9) . vSIVgpl3O was generated by homologous recombination between VV (WR) and pVYSIVmacgpl3O in CV-1 cells (3) . Expression and purification of gpl30 in mammalian (CHO) cells (cSIVgpl30) has been described previously (34) .
For the construction of baculovirus expression vector, the Anti-SIV gpl30 antibodies were determined by enzymelinked immunosorbent assay (ELISA) with bSIVgpl30 as a coating antigen (Fig. 1 ). The choice of this antigen over cSIVgpl30 (antigen used for immunization) minimized anti- (31) .
c Titer was the reciprocal of the dilution of serum which gave 50% plaque reduction of VV on BSC-1 cells (42) . Neutralization titers of serum dilutions of <10 were not determined.
d ND, neutralization titers of serum dilutions of <8 were not determined.
vested, and the gpl3O concentration (adjusted to 2 ,ug/ml in carbonate-bicarbonate buffer [pH 9.5]) was used to coat microtiter plates (Immulon II; Dynatech Laboratories, Alexandria, Va.). Test sera were serially diluted (twofold), and horseradish peroxidase-labelled antimonkey immunoglobulin was used as the secondary antibody (Cappel, Inc., West Chester, Pa.). The anti-SIV gpl3O titers were read as the reciprocal of the serum dilution giving greater than two times the optical density reading of the negative control serum. Animals in group A (vSIVgpl3O plus cSIVgpl3O) developed anti-gpl30 titers of <100 after both vSIVgpl3O immunizations. However, there was a dramatic increase in anti-gpl3O titer (>1,500) after booster injection with cSIVgpl3O. In contrast, group B animals (vSIVgpl3O alone) had low antigpl3O titers of 100 throughout the immunization phase of the study. Animals in group C (cSIVgpl3O) had an anti-gpl3O titer of <500 after three consecutive immunizations (Fig. 1) . The titer dropped to < 100 2 weeks before challenge, and the last immunization of the group resulted in an anamnestic response with titers of 600.
Anti-SIVmaclAll SN antibodies were determined by measuring inhibition of SIV gpl3O production as previously described (34) . No an anamnestic response followed the booster immunization ( Table 2) .
Challenge of rhesus macaques with pathogenic SIV. The preparation and in vivo titration of cell-free SIVmac challenge stock have been described (28) . All immunized animals and two naive macaques were challenged by intravenous inoculation with 1 to 10 100% animal infectious doses (IDico) 2 weeks after the last booster injection (i.e., 24 
weeks after primary immunization).
Blood samples were collected in heparinized tubes at various time intervals after challenge, and peripheral blood mononuclear cells (PBMC) from these samples were isolated on a Ficoll gradient and cocultured with CEM-X-174 cells. Cultures were monitored for SIV replication by an antigen capture ELISA with the monoclonal antibody 55F12, which is specific for SIVmac p27 (21) . One week after challenge, SIV was isolated from PBMC of the two naive controls and 11 of 12 immunized macaques. Two weeks postchallenge, PBMC from all were positive for virus and remained positive for the duration of the study (4 months). Antigenemia levels were measured by a commercial SIV core (p27) antigen capture ELISA (Coulter SIV Core Antigen Assay; Retrovirology Coulter Corp., Hialeah, Fla.). The sensitivity of this assay allows the detection of 0.050 ng of SIV p27 per ml. SIV p27-Gag antigenemia was detected 2 weeks after challenge in the two controls and 11 of the 12 immunized animals; macaque 17081 (vSIVgpl30 plus cSIVgpl30) was negative until week 15 after challenge. Although the antigenemia pattern was similar for immunized and control macaques, the antigen load appeared to be higher for nonimmunized animals (Fig. 2) . After challenge, unimmunized animals had values ranging from 0.464 to 3.26 ng/ml compared with 0.059 to 0.141 ng/ml for the immunized groups. Macaque 21773 (vaccinated with vSIVgpl30 plus cSIVgpl30) showed an increased level of antigenemia 9 weeks after challenge.
After challenge, the anti-gpl30 antibody titers steadily increased in all groups of animals, presumably due to an anamnestic response associated with the replication of challenge virus (Fig. 1) . In group A animals (vSIVgpl30 plus cSIVgpl30), the titers peaked at >2,500 by 2 weeks after challenge as a result of anamnestic responses to the last booster vaccination and replication of challenge virus. Later, the anti-gpl30 titer steadily declined to a level of 500 by 40 weeks after primary immunization. One animal (21678) had a peak titer of 2,000 by 2 weeks after challenge that declined to 1,500 by 40 weeks after primaxy immunization. Three of the four animals in group C (cSIVgpl30 alone) had immune responses similar to those in group A except that the peak ELISA titers were lower (1,000). The fourth animal had a steadily increasing titer, approaching 2,000 by 40 weeks after primary immunization.
Anti-SIV SN antibodies were transient or not detected in group A and C macaques and completely absent in group B ( Table 2 ). The immune response of macaques was studied further by Western blot analysis. All immunized animals showed antibodies directed exclusively against gpl30 before challenge. Samples taken 4 months after challenge showed the presence of antibodies directed against other SIV proteins as well (Fig. 3) . Specific, reactive bands were more intense, however, in vaccinated animals and weak in controls. This observation has also been noted for other viruses. For instance, priming of mice with a single synthetic T-cell epitope, located in the hepatitis B virus nucleocapsid protein, helped B cells to produce antibodies against envelope antigens as well as nucleocapsid protein, even though these antigens are found on separate molecules (27) . The presence of T-helper-cell epitopes in SIV gpl30 was not shown consistently in T-cell proliferation assays. However, this could explain why macaques immunized with gpl30 developed higher antibody titers against other SIV antigens when compared with unimmunized controls (Fig. 3b) . We observed an inverse relationship between the levels of antigenemia and antibody. This is best illustrated by macaque 21773 (vSIVgpl30 plus cSIVgpl30), the animal exhibiting the weakest Western blot response along with increasing antigenemia (0.162 to 0.251 ng/ml) 9 weeks after challenge (Fig.  3a) .
PBMC were obtained from heparinized blood by centrifugation in Ficoll-Hypaque gradients. T-cell proliferation assays were performed on macaque PBMC with concanavalin A and cSIVgpl30 as the stimulants (34) . All three groups developed variable and inconsistent proliferative immune responses against cSIVgpl30 during the immunization period. After challenge, no proliferative response to cSIV gpl30 was detected (data not shown). Evaluation of gpl30 as immunogen. The potential of SIV gpl30 as an effective vaccine against live virus challenge was tested in rhesus macaques immunized with various preparations of the antigen. SIV gpl30 expressed in CHO cells and in VV was used as the immunogen, and these experiments included immunization of macaques with cSIVgpl30, vSIV gpl30, and a combination of both preparations.
We chose the WR strain of VV and the hemagglutinin gene for the insertion of the coding sequence of gpl30 in order to obtain higher levels of expression of the protein. The WR strain replicates and reaches titers at least 1 log higher than the Wyeth strain, and VV is less attenuated by insertional inactivation of the hemagglutinin gene than by the thymidine kinase gene (12) . Presumably due to the reduced level of attenuation, about one-half of the animals developed severe skin lesions after primary immunization. These lesions healed in 1 month and did not recur after a second immunization with vSIVgpl3O.
Serum ELISA antibody titers to gpl30 were significantly higher in animals vaccinated with vSIVgpl30 and then boosted with cSIVgpl30 than in animals vaccinated with either immunogen alone. Immunologic priming with a VV recombinant followed by booster immunization with a particulate antigen to obtain a strong immune response has been described previously (lla, 17) . Protective immunization against SIV in rhesus macaques has been achieved with inactivated or modified live whole-virus vaccines (2, 7, 19, 30) or inactivated-SIV-infected cell vaccine (38) . Partial protection has been accomplished with viral subunit preparations such as native envelope-enriched vaccine (31, 32) and a combination of ,B-galactosidase-SIV Env epitope fusion proteins (36) . More recently, Hu et al. (17) reported that macaques immunized with VY recombinants expressing SIVmne gpl60 and then boosted with baculovirus-expressed SIVmne gpl60 were protected against intravenous challenge with the homologous, biologically cloned SIVmne. There are a number of differences in our study that could account for the lack of protection we found. In the study of Hu et al. (17) , macaques (Macaca fasicularis) were vaccinated with the immunogen obtained from SIVmne and then challenged with the homologous, biological clone. We used a different species, M. mulatta, and the source of both immunogen and challenge virus was SIVmac. Differences in the virulence of SIV isolates and/or differences in the immune responses of macaque species may affect the elicitation of protective immunity against SIV infection. The same dose of the identical challenge stock of SIVmac used in our experiment has been shown to produce persistent, fatal infection in unvaccinated rhesus macaques inoculated intravenously; all animals died with clinical signs of immunodeficiency within 22 to 41 weeks postchallenge (25) . In contrast, the biological clone of SIVmne used for challenge in the study of Hu et al. (17) has low genetic diversity and induces an intermittent viremia in about one-half of the unvaccinated cynomolgus macaques (17) . The period for development of fatal immunodeficiency with SIVmne can take much longer than for SIVmac (11) .
In our study, the gp130-coding sequence was derived from SIVmaclAll, a nonpathogenic molecular clone of SIVmac, the biological isolate used as a challenge virus. Tissue culture isolates of SIVmac do not account for the complete spectrum of genotypes present in an infected macaque (15) . Therefore, the SIVmaclA11 genome probably represents a low proportion of the genomes found in the biological, uncloned SIVmac. In consequence, the conditions of our challenge can be defined as heterogeneous. In other lentivirus systems, it has been demonstrated that a single amino acid substitution at a critical residue in the envelope glycoprotein resulted in the alteration of a major biological function of a molecule. For example, a point mutation in the V3 loop of HIV-1 gp120 alters the pattern of cell tropism and susceptibility to neutralization (4).
Another important difference that could account for protection in the study of Hu et al. (17) is the immunization of macaques with the external and transmembrane domains of the SIV envelope glycoprotein (gpl60). Our monkeys were immunized with the external envelope glycoprotein (gpl30) only. It is possible that immune responses directed toward the transmembrane domain are essential for protection against SIV. In all the successful experimental protocols, the envelope glycoprotein was present either as precursor gp160 or as mature proteins gp130 and gp4l. Even when conserved epitopes were used for immunization, they represented portions of both gp130 and gp4l (36) . In the present study, we report the lack of protection in groups of animals vaccinated with cSIVgpl30, vSIVgpl30, or a combination of both preparations. The absence of gp4l in our vaccine preparation might have contributed to the failure of protection. In this regard, experiments are in progress to evaluate gpl60 as a protective immunogen.
Finally, no SN antibodies were detected in our studies, and they may be required for protective immunity. The role of SN antibodies in protection is still controversial. Correlation between protection and neutralization with inactivated whole-virus vaccine has been observed but not consistently (11) . Furthermore, we did not measure or determine the role of enhancing antibodies which might have contributed to lack of protection. However, it is known that inactivated SIV vaccines can protect macaques from infection even in the presence of detectable enhancing antibodies (29) .
Our data did not corroborate the successful protection studies against HIV-1 infection in chimpanzees vaccinated with HIV gp120 expressed in CHO cells (1) . Several differences exist between the two studies that might affect the results. First, there are distinct immunochemical differences between SIV gp130 and HIV gp120 (5). For example, an equivalent immunodominant V3 loop of HIV gp120 has not been found in SIV gp130 (18) . The primary amino acid sequences and the glycosylation pattern of the two molecules are also different (16, 22) .
In our study, delay in the onset of simian AIDS has not been included as one of the parameters for evaluating the effectiveness of a vaccine. A number of whole-virus vaccine preparations have significantly delayed the onset of clinical disease in infected vaccinates (25, 32, 40) .
In summary, recombinant SIV gp130 delivered either alone as a live recombinant vaccine in VV or boosted with a purified cSIVgp130 failed to provide protective immunity to rhesus macaques challenged with a low dose of pathogenic SIVmac 251. However, the group primed with vSIVgp130 and then boosted with cSIVgp130 had the lowest virus load We thank Andrew Lackner for assistance on studies of VV pock lesions in macaques and Linda Antipa and Steven Joyce for technical assistance.
